Ethambutol ( DrugBank: Ethambutol )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
84サルコイドーシス2
299嚢胞性線維症1

84. サルコイドーシス


臨床試験数 : 149 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02024555
(ClinicalTrials.gov)
March 201426/12/2013Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary SarcoidosisInvestigation of the Efficacy of Antimycobacterial Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled TrialSarcoidosis; Antimycobacterial TherapyDrug: Levofloxacin;Drug: Ethambutol;Drug: Azithromycin;Drug: Rifampin;Drug: PlaceboVanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed18 YearsN/AAll97Phase 2United States
2NCT01169038
(ClinicalTrials.gov)
July 201022/7/2010Investigation of the Efficacy of Antibiotics on Pulmonary SarcoidosisInvestigation of the Efficacy of Antibiotics on Pulmonary SarcoidosisPulmonary Sarcoidosis;Lung FunctionDrug: levaquin; ethambutol; rifampin and azithromycin.Vanderbilt UniversityNULLCompleted18 Years75 YearsAll15Phase 1United States

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02372383
(ClinicalTrials.gov)
October 201420/6/2014Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic FibrosisPharmacokinetic Evaluation of Nontuberculous Mycobacterial Antibiotics in Cystic Fibrosis Versus ControlsCystic FibrosisDrug: Ethambutol;Drug: Rifampin;Drug: Azithromycin;Drug: PancrelipaseUniversity of Colorado, DenverCystic Fibrosis Foundation Therapeutics;Colorado Clinical & Translational Sciences InstituteCompleted16 Years45 YearsBoth32N/AUnited States